Patricia A. Madureira

Gambelas, 8005139, Portugal

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.

Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.

Journal: Nature communications
Published: July 19, 2023

Androgens and low density lipoprotein-cholesterol interplay in modulating prostate cancer cell fate and metabolism.

Androgens and low density lipoprotein-cholesterol interplay in modulating prostate cancer cell fate and metabolism.

Journal: Pathology, research and practice
Published: July 28, 2022

Retraction notice to " IP1867B suppresses the Insulin-like Growth Factor 1 Receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas" [Canc. Lett., 458 (2019) pages 29-38].

Retraction notice to " IP1867B suppresses the Insulin-like Growth Factor 1 Receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas" [Canc. Lett., 458 (2019) pages 29-38].

Journal: Cancer letters
Published: March 20, 2021

The Role of Hypoxia in Glioblastoma Radiotherapy Resistance.

The Role of Hypoxia in Glioblastoma Radiotherapy Resistance.

Journal: Cancers
Published: December 28, 2020

Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.

Glutaminolysis is a metabolic route essential for survival and growth of prostate cancer cells and a target of 5α-dihydrotestosterone regulation.

Journal: Cellular oncology (Dordrecht, Netherlands)
Published: November 17, 2020

Investigating Glioblastoma Response to Hypoxia.

Investigating Glioblastoma Response to Hypoxia.

Journal: Biomedicines
Published: August 06, 2020

Corrigendum to "IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas." [Cancer Lett. 458C (2019) 29-38].

Corrigendum to "IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas." [Cancer Lett. 458C (2019) 29-38].

Journal: Cancer letters
Published: October 13, 2019

Retraction: DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death.

Retraction: DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death.

Journal: Oncotarget
Published: October 01, 2019

DIVERSet JAG Compounds Inhibit Topoisomerase II and Are Effective Against Adult and Pediatric High-Grade Gliomas.

DIVERSet JAG Compounds Inhibit Topoisomerase II and Are Effective Against Adult and Pediatric High-Grade Gliomas.

Journal: Translational oncology
Published: June 25, 2019

Annexin A2 Regulates AKT Upon H₂O₂-Dependent Signaling Activation in Cancer Cells.

Annexin A2 Regulates AKT Upon H₂O₂-Dependent Signaling Activation in Cancer Cells.

Journal: Cancers
Published: March 14, 2019

RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.

RETRACTED: IP1867B suppresses the insulin-like growth factor 1 receptor (IGF1R) ablating epidermal growth factor receptor inhibitor resistance in adult high grade gliomas.

Journal: Cancer letters
Published: February 22, 2019

Immune aging in diabetes and its implications in wound healing.

Immune aging in diabetes and its implications in wound healing.

Journal: Clinical immunology (Orlando, Fla.)
Published: January 02, 2019
Showing 1-12 of 24

Last Updated: 09/26/2026